The cost-effectiveness institute for England and Wales has rejected three biological treatments for metastatic colorectal cancer that has progressed after initial or second-line treatment. The National Institute for Health and Clinical Excellence (NICE) said Jan. 24 that cetuximab (Erbitux, Merck Serono SA), bevacizumab (Avastin, Roche) and panitumumab (Vectibix, Amgen Inc.) had all failed to reach the agency’s cost-effectiveness criteria for the treatment of metastatic colorectal cancer that has...